A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.
OBJECTIVE
This study aimed at evaluating the cost-effectiveness of human papillomavirus virus (HPV) vaccination in France, using a generally applicable succinct cohort model.


METHODS
A lifetime Markov cohort model, adapted to the French setting, simulate the natural history of oncogenic HPV infection towards cervical cancer (CC). Additional modules account for the effects of screening and vaccination. The girls' cohort is vaccinated at age 12 and follows current screening. Costs and outcomes (discounted at 3 and 1.5%, respectively) were compared with a cohort receiving screening alone.


RESULTS
The model results agreed well with real-life data. Vaccination in addition to screening would substantially reduce the incidence of and mortality from CC, compared with screening alone, at an estimated cost-effectiveness of <euro>9,706 per quality-adjusted-life-year. Sensitivity analysis showed that the discount rate and the parameters related to the disease history have the largest impact on the results.


CONCLUSIONS
This succinct cohort model indicated that HPV vaccination would be a cost-effective policy option in France. It uses readily available data and should be generally applicable to the evaluation of HPV vaccination in a variety of countries and settings.
Health Economics, GlaxoSmithKline Biologicals, Wavre, Belgium. nadia.x.demarteau@gskbio.com
Nadia
N
Demarteau
Bruno
B
Detournay
Bertrand
B
Tehard
Abdelkader
A
El Hasnaoui
Baudouin
B
Standaert
D002648:Child; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D005260:Female; D005602:France; D006801:Humans; D015994:Incidence; D008390:Markov Chains; D017059:Models, Econometric; D030361:Papillomavirus Infections / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics*; D002583:Uterine Cervical Neoplasms / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*; D014611:Vaccination / Q000191:economics
D053918:Papillomavirus Vaccines